Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by bcjton Feb 07, 2012 4:27pm
559 Views
Post# 19501824

Oncolytics to list 5.06 million more shares Feb. 8

Oncolytics to list 5.06 million more shares Feb. 8

Oncolytics Biotech Inc (C:ONC)
Shares Issued 71,251,335
Last Close 2/6/2012 $5.37
Tuesday February 07 2012 - Prospectus Approved

Oncolytics Biotech Inc. will list an additional 5,065,750 shares on the Toronto Stock Exchange at the open on Wednesday, Feb. 8, 2012, according to the TSX. As in a Jan. 25, 2012, prospectus supplement, Oncolytics plans to sell 4,405,000 shares at $4.20 each, raising $18,501,000. It has granted the underwriters an overallotment option to buy up to 660,750 more shares at the same price for 30 days from the closing of the offering. It plans to use the money raised for its continuing head and neck cancer study, for research and development, for manufacturing, and for general corporate purposes.

© 2012 Canjex Publishing Ltd.

Bullboard Posts